GlycoFi owns or controls over 60 issued and pending patents in the U.S. and abroad relating to glycosylation engineering and the production of human glycoproteins with proper glycosylation in yeast and fungi. Additionally, we have in-licensed complementary protein expression technology. GlycoFi’s strategy is to secure global intellectual property protection for our protein expression technology, as well as specific glycan structure-protein activity relationships.
Printer Friendly Page
